(Q34009569)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214569%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

review article

1 reference

title

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214569%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author

Robert Graham G Russell

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214569%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Michael J. Rogers

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214569%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

N B Watts

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214569%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

F H Ebetino

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214569%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

language of work or name

English

0 references

publication date

1 June 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214569%20AND%20SRC:MED&resulttype=core&format=json

Osteoporosis International

1 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214569%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214569%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

733-759

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214569%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214569%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00198-007-0540-8

1 January 2020

exact match

0 references

cites work

Bisphosphonates: from bench to bedside

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Diphosphonates and Page's disease of bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Diphosphonates in the treatment of myositis ossificans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

New Insights Into the Molecular Mechanisms of Action of Bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Recent advances in understanding the mechanism of action of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Osteocytes as dynamic multifunctional cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Fas/CD95 is associated with glucocorticoid-induced osteocyte apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Bisphosphonates act on rat bone resorption through the mediation of osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Hypercalcemia induced with an arotinoid in thyroparathyroidectomized rats. New model to study bone resorption in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Bisphosphonates: a review of their pharmacokinetic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix gamma-carboxyglutamic acid protein in the serum of etidronate-treated rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Bisphosphonates in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

The role of bisphosphonates in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Osteogenesis imperfecta, current and future medical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Severely suppressed bone turnover: a potential complication of alendronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Bisphosphonate-induced osteopetrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Zoledronic acid causes enhancement of bone growth into porous implants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Zoledronic Acid Treatment Results in Retention of Femoral Head Structure After Traumatic Osteonecrosis in Young Wistar Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Zoledronic acid improves femoral head sphericity in a rat model of perthes disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Zoledronic acid and clinical fractures and mortality after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Efficacy of risedronate on clinical vertebral fractures within six months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

The use of cyclical etidronate in osteoporosis: changes after completion of 3 years treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Fracture risk remains reduced one year after discontinuation of risedronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Risedronate reduces the risk of first vertebral fracture in osteoporotic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Solid-state NMR, crystallographic, and computational investigation of bisphosphonates and farnesyl diphosphate synthase-bisphosphonate complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Comparison of Weekly Treatment of Postmenopausal Osteoporosis with AlendronateVersusRisedronate Over Two Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0540-8

Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats

21 January 2018

1 reference

12 December 2020

Clodronate kinetics and dynamics

1 reference

12 December 2020

1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase

1 reference

12 December 2020

Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs

1 reference

12 December 2020

Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis

1 reference

12 December 2020

Effect of pyrophosphate on dissolution of hydroxyapatite and its possible importance in calcium homeostasis.

1 reference

12 December 2020

Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo

1 reference

12 December 2020

1 reference

12 December 2020

Long-term safety of bisphosphonates

1 reference

12 December 2020

The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised r

1 reference

12 December 2020

Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.

1 reference

12 December 2020

Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study

1 reference

12 December 2020

Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy

1 reference

12 December 2020

The long-term skeletal effects of EHDP in dogs

1 reference

12 December 2020

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

12 December 2020

A systematic review of the role of bisphosphonates in metastatic disease

1 reference

12 December 2020

The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease

1 reference

12 December 2020

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats

1 reference

12 December 2020

Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers

1 reference

12 December 2020

Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones

1 reference

12 December 2020

The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part I of IV parts: mechanisms of calcium transfer between blood and bone and their cellular basis: morphological a

1 reference

12 December 2020

Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate

1 reference

12 December 2020

Antiresorptive dose-response relationships across three generations of bisphosphonates

1 reference

12 December 2020

PTH and interactions with bisphosphonates

1 reference

12 December 2020

10.1007/S00198-007-0540-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18214569%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

1 January 2020

0 references

1 reference